-transparent.png){kind=logo}
46 adults with previously untreated acute myelogenous leukaemia who achieved complete remission with 6-thioguanine, cytarabine, and daunorubicin (TAD) received two courses of intensive consolidation chemotherapy. The first cycle consisted of 5-azacytidine and doxorubicin followed by a second consolidation cycle with TAD. Maintenance chemotherapy was not administered. Median remission duration was 14 months and 26% (95% confidence interval, 11%-41%) remained in continuous remission at 5 years. Actuarial 5 year survival was 31% (+/- 15%). Results were most favourable in patients who achieved complete remission within 60 days of chemotherapy being initiated. These data indicate that prolonged disease-free survival can be achieved in patients treated with intensive induction and consolidation treatment alone without maintenance chemotherapy.
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
February 1984,
Lancet (London, England),
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
January 1991,
Bailliere's clinical haematology,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
May 1981,
British medical journal (Clinical research ed.),
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
July 1981,
British medical journal (Clinical research ed.),
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
October 1972,
Journal of the Irish Medical Association,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
March 1983,
Scandinavian journal of haematology,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
September 1977,
British medical journal,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
August 1977,
British medical journal,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
March 1980,
British journal of cancer,
R Champlin, and
A Jacobs, and
R P Gale, and
R Boccia, and
R Elashoff, and
K Foon, and
J Zighelboim
August 2023,
Journal of pediatric hematology/oncology,
